Genenta Science S.p.A. (SAEN)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Conglomerates
Genenta Science S.p.A.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.6798 | 0.6798 | 0.5719 | 0.5770 | 46,490 |
| Nov 16, 2026 | 0.6300 | 0.6300 | 0.5900 | 0.6000 | 36,367 |
| Nov 13, 2026 | 0.6241 | 0.6701 | 0.6005 | 0.6498 | 18,860 |
| Nov 12, 2026 | 0.7000 | 0.7000 | 0.6204 | 0.6240 | 18,719 |
| Nov 11, 2026 | 0.7002 | 0.7149 | 0.6648 | 0.6800 | 8,487 |
| Nov 10, 2026 | 0.7470 | 0.7470 | 0.6801 | 0.7179 | 32,825 |
| Nov 9, 2026 | 0.6769 | 0.7206 | 0.6250 | 0.6801 | 25,233 |
| Nov 6, 2026 | 0.6450 | 0.7199 | 0.5999 | 0.6650 | 107,604 |
| Nov 5, 2026 | 0.6691 | 0.6832 | 0.5553 | 0.6497 | 158,708 |
| Nov 4, 2026 | 0.7800 | 0.8000 | 0.6600 | 0.7000 | 189,888 |
| Nov 3, 2026 | 0.8359 | 0.9900 | 0.8189 | 0.9850 | 337,503 |
| Nov 2, 2026 | 0.6611 | 0.8700 | 0.6611 | 0.8166 | 1,575,056 |
| Oct 30, 2026 | 0.6200 | 0.6365 | 0.6000 | 0.6183 | 67,198 |
| Oct 29, 2026 | 0.5997 | 0.6200 | 0.5801 | 0.6200 | 153,196 |
| Oct 28, 2026 | 0.5820 | 0.6300 | 0.5820 | 0.6050 | 42,193 |
| Oct 27, 2026 | 0.6330 | 0.6369 | 0.5910 | 0.6182 | 18,900 |
| Oct 26, 2026 | 0.6150 | 0.6340 | 0.5955 | 0.6244 | 28,856 |
| Oct 23, 2026 | 0.6399 | 0.6399 | 0.6300 | 0.6300 | 13,372 |
| Oct 22, 2026 | 0.6610 | 0.6610 | 0.6301 | 0.6301 | 36,968 |
| Oct 21, 2026 | 0.6100 | 0.6598 | 0.6100 | 0.6400 | 36,764 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CMO& Head of Development | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Chief Financial Officer | Grant/Award | 80.0K | -- | Mar 30, 2026 | |
| Chief Executive Officer | Grant/Award | 100.0K | -- | Mar 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Globe 2017 S.r.l. · joint filing· may incl. warrants· filed Oct 2026 | 5.5M | 11.5% | 13D |
Pierluigi Paracchi · may incl. warrants· filed Jan 2026 | 2.3M | 9.8% | 13G |
Eurizon Capital SGR S.p.A. | 360.0K | -- | 13F |
ALLIANZ SE | 234.1K | -- | 13F |
AlTi Global, Inc. | 200.3K | -- | 13F |
CITADEL ADVISORS LLC | 191.0K | -- | 13F |
BNP PARIBAS FINANCIAL MARKETS | 47.0K | -- | 13F |
JANE STREET GROUP, LLC | 42.1K | -- | 13F |
Mutti Miguel Maria Director | 33.3K | -- | FORM 4 |
TWO SIGMA SECURITIES, LLC | 29.2K | -- | 13F |
Insiders
- Galimi FrancescoCMO& Head of Development
- PARACCHI GIACOMOANTONIODirector
- Sharei ArmonDirector
- Mutti Miguel MariaDirector
- SLANSKY RICHARD BChief Financial Officer
- Pierluigi ParacchiChief Executive Officer
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors.
Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
based on 48.22M shares outstanding
30d Avg
141.25K
60d Avg
102.04K
90d Avg
85.98K
Signal8's dilution snapshot of SAEN as of Dec 31, 2025 records 1 outstanding warrant series, from SEC filings. Genenta Science S.p.A. (NASDAQ: SAEN) traded at $0.5770 on Nov 17, 2026, down 3.83% from the previous close of $0.6000. 52-week range: $0.5500 to $2.58. The company is in the Industrials sector (Aerospace & Defense).